|1.||Wolf, Michael: 2 articles (01/2013 - 05/2012)|
|2.||Greenberg, Brittany E: 2 articles (01/2013 - 05/2012)|
|3.||Wurz, Gregory T: 2 articles (01/2013 - 05/2012)|
|4.||Sangha, Randeep: 2 articles (11/2007 - 08/2007)|
|5.||North, Scott: 2 articles (11/2007 - 06/2005)|
|6.||Butts, Charles: 2 articles (08/2007 - 06/2005)|
|7.||Wang, Jie: 1 article (10/2014)|
|8.||Xu, Lin: 1 article (10/2014)|
|9.||Xia, Wenjie: 1 article (10/2014)|
|10.||Jiang, Feng: 1 article (10/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
01/01/2013 - "A single cycle of L-BLP25 consisting of eight weekly doses was ineffective, whereas adding a second cycle given during tumor progression showed a significant reduction in the incidence of tumor foci. "
01/01/2011 - "The primary objective of the INSPIRE study is to assess the treatment effect of L-BLP25 plus best supportive care (BSC), as compared to placebo plus BSC, on overall survival time in East-Asian patients with unresectable stage III NSCLC and either documented stable disease or an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria following primary chemoradiotherapy. "
01/01/2013 - "Antitumor activity of L-BLP25 (10 μg) with CPA (100 mg/kg) pretreatment was evaluated following either one or two eight-week cycles of treatment by preparing lung whole mounts and counting tumor foci, and assessing IFN-γ production by ELISpot assay. "
11/01/2007 - "These encouraging results suggest the potential of L-BLP25 in the management of cancer."
01/01/2012 - "Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/01/2007 - "These promising results will be tested in a phase III trial of L-BLP25 versus placebo in patients with stage III non-small cell lung cancer after response to primary chemoradiotherapy."
11/01/2007 - "A Phase II study in advanced non-small cell lung cancer demonstrated a strong survival trend in favour of L-BLP25 in a subgroup of patients with locoregional stage IIIB disease. "
08/01/2007 - "A randomized phase II trial of maintenance L-BLP25 versus best supportive care in patients with stage IIIB/IV non-small cell lung cancer who experienced clinical benefit from initial therapy has been reported. "
06/01/2005 - "Studies in advanced-stage non-small cell lung cancer demonstrate that L-BLP25 vaccine has the potential to extend the survival of patients with Stage IIIB locoregional non-small cell lung cancer and maintain quality of life for longer. "
10/01/2014 - "L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review."
|4.||Melanoma (Melanoma, Malignant)
06/01/2012 - "In NSCLC, ongoing phase III trials are investigating this approach in different treatment settings: the Melanoma AntiGEn A3 vaccine in resected early-stage NSCLC, the L-BLP25 vaccine in locally advanced NSCLC after chemoradiotherapy, and belagenpumatucel-L, the epidermal growth factor and the TG4010 vaccine in advanced stage, either as an adjunct to chemotherapy or as maintenance after completion of chemotherapy. "
06/01/2008 - "This article reviews the following seven vaccines, which have entered randomized trials: L-BLP25 (Stimuvax), BEC-2, 1E10, PF-3512676 (Promune), melanoma-associated antigen A3 immunotherapeutic, granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy, and belagenpumatucel-L (Lucanix)."
|2.||Prostate-Specific Antigen (Semenogelase)
|3.||Urethane (Ethyl Carbamate)
|7.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|10.||Epidermal Growth Factor (EGF)
|1.||Prostatectomy (Retropubic Prostatectomy)
|3.||Drug Therapy (Chemotherapy)